Clinical Trials Browser

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

Phase 2 Recruiting

35 enrolled

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT06130995 2026-03-05

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Phase 1 Recruiting

46 enrolled

Pathologic Complete Response, Neoplasm, Residual

NCT04055220 2026-02-17

REGOSTA

Phase NA Recruiting

168 enrolled

Sarcoma

Pathologic Complete Response, Bone Neoplasms, Chondrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Patient Compliance, Sarcoma, Ewing, Osteosarcoma, Histiocytoma, Malignant Fibrous

NCT07353840 2026-01-20

T-START-CR

Recruiting

160 enrolled

Lymphoid

Pathologic Complete Response, Lymphoma, T-Cell, Peripheral

NCT07328841 2026-01-09

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

Phase 3 Recruiting

456 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT07328854 2026-01-09

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

Phase 3 Recruiting

346 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT07066189 2025-10-29

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

Phase NA Recruiting

160 enrolled

Breast

Pathologic Complete Response, Motor Activity, Triple Negative Breast Neoplasms

NCT07166185 2025-09-10

NEOTRAPSCAL

Recruiting

70 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT06811844 2025-07-01

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

Phase 2 Recruiting

208 enrolled

Head & Neck

Pathologic Complete Response, Nasopharyngeal Neoplasms

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Phase 2 Recruiting

180 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT05416164 2025-03-26

DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy

Phase NA Recruiting

595 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT05976815 2025-03-26

KEYMOVE

Phase NA Recruiting

86 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms, Motor Activity

Clinical Trials

I-SPY

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

REGOSTA

T-START-CR

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

NEOTRAPSCAL

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy

KEYMOVE